Annual CAPEX
$674.00 K
+$261.00 K+63.20%
31 December 2023
Summary:
Lineage Cell Therapeutics annual capital expenditures is currently $674.00 thousand, with the most recent change of +$261.00 thousand (+63.20%) on 31 December 2023. During the last 3 years, it has risen by +$610.00 thousand (+953.12%). LCTX annual CAPEX is now -87.36% below its all-time high of $5.33 million, reached on 31 December 2015.LCTX CAPEX Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CAPEX
$112.00 K
+$62.00 K+124.00%
30 September 2024
Summary:
Lineage Cell Therapeutics quarterly capital expenditures is currently $112.00 thousand, with the most recent change of +$62.00 thousand (+124.00%) on 30 September 2024. Over the past year, it has dropped by -$27.00 thousand (-19.42%). LCTX quarterly CAPEX is now -95.43% below its all-time high of $2.45 million, reached on 30 June 2015.LCTX Quarterly CAPEX Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CAPEX
$291.00 K
-$27.00 K-8.49%
30 September 2024
Summary:
Lineage Cell Therapeutics TTM capital expenditures is currently $291.00 thousand, with the most recent change of -$27.00 thousand (-8.49%) on 30 September 2024. Over the past year, it has dropped by -$276.00 thousand (-48.68%). LCTX TTM CAPEX is now -94.99% below its all-time high of $5.81 million, reached on 31 March 2016.LCTX TTM CAPEX Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
LCTX CAPEX Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +63.2% | -19.4% | -48.7% |
| 3 y3 years | +953.1% | +64.7% | +33.5% |
| 5 y5 years | -79.5% | +62.3% | -79.9% |
LCTX CAPEX High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +953.1% | -60.8% | +800.0% | -59.2% | +33.5% |
| 5 y | 5 years | -79.5% | +953.1% | -60.8% | +800.0% | -79.9% | +519.1% |
| alltime | all time | -87.4% | >+9999.0% | -95.4% | +144.8% | -95.0% | +5605.9% |
Lineage Cell Therapeutics CAPEX History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $112.00 K(+124.0%) | $291.00 K(-8.5%) |
| June 2024 | - | $50.00 K(+31.6%) | $318.00 K(-39.3%) |
| Mar 2024 | - | $38.00 K(-58.2%) | $524.00 K(-22.3%) |
| Dec 2023 | $674.00 K(+63.2%) | $91.00 K(-34.5%) | $674.00 K(+18.9%) |
| Sept 2023 | - | $139.00 K(-45.7%) | $567.00 K(-20.6%) |
| June 2023 | - | $256.00 K(+36.2%) | $714.00 K(+28.6%) |
| Mar 2023 | - | $188.00 K(-1275.0%) | $555.00 K(+34.4%) |
| Dec 2022 | $413.00 K(+21.5%) | -$16.00 K(-105.6%) | $413.00 K(-28.2%) |
| Sept 2022 | - | $286.00 K(+194.8%) | $575.00 K(+61.1%) |
| June 2022 | - | $97.00 K(+110.9%) | $357.00 K(-4.8%) |
| Mar 2022 | - | $46.00 K(-68.5%) | $375.00 K(+10.3%) |
| Dec 2021 | $340.00 K(+431.3%) | $146.00 K(+114.7%) | $340.00 K(+56.0%) |
| Sept 2021 | - | $68.00 K(-40.9%) | $218.00 K(+25.3%) |
| June 2021 | - | $115.00 K(+945.5%) | $174.00 K(+167.7%) |
| Mar 2021 | - | $11.00 K(-54.2%) | $65.00 K(+1.6%) |
| Dec 2020 | $64.00 K(-85.5%) | $24.00 K(0.0%) | $64.00 K(+36.2%) |
| Sept 2020 | - | $24.00 K(+300.0%) | $47.00 K(-48.9%) |
| June 2020 | - | $6000.00(-40.0%) | $92.00 K(-67.3%) |
| Mar 2020 | - | $10.00 K(+42.9%) | $281.00 K(-36.1%) |
| Dec 2019 | $440.00 K(-86.6%) | $7000.00(-89.9%) | $440.00 K(-69.6%) |
| Sept 2019 | - | $69.00 K(-64.6%) | $1.45 M(-44.6%) |
| June 2019 | - | $195.00 K(+15.4%) | $2.61 M(+6.3%) |
| Mar 2019 | - | $169.00 K(-83.4%) | $2.46 M(-25.2%) |
| Dec 2018 | $3.29 M(+147.9%) | $1.02 M(-17.7%) | $3.29 M(+23.2%) |
| Sept 2018 | - | $1.23 M(+3064.1%) | $2.67 M(+41.2%) |
| June 2018 | - | $39.00 K(-96.1%) | $1.89 M(-10.4%) |
| Mar 2018 | - | $998.00 K(+152.0%) | $2.11 M(+59.0%) |
| Dec 2017 | $1.33 M(-47.5%) | $396.00 K(-13.2%) | $1.33 M(+0.6%) |
| Sept 2017 | - | $456.00 K(+76.1%) | $1.32 M(-1.5%) |
| June 2017 | - | $259.00 K(+20.5%) | $1.34 M(-29.2%) |
| Mar 2017 | - | $215.00 K(-44.6%) | $1.89 M(-25.1%) |
| Dec 2016 | $2.53 M(-52.6%) | $388.00 K(-18.5%) | $2.53 M(-19.2%) |
| Sept 2016 | - | $476.00 K(-41.4%) | $3.13 M(-25.0%) |
| June 2016 | - | $812.00 K(-4.5%) | $4.17 M(-28.2%) |
| Mar 2016 | - | $850.00 K(-14.1%) | $5.81 M(+8.9%) |
| Dec 2015 | $5.33 M(+659.8%) | $990.00 K(-34.9%) | $5.33 M(+17.3%) |
| Sept 2015 | - | $1.52 M(-37.9%) | $4.55 M(+45.8%) |
| June 2015 | - | $2.45 M(+556.8%) | $3.12 M(+270.1%) |
| Mar 2015 | - | $373.00 K(+82.0%) | $843.10 K(+20.1%) |
| Dec 2014 | $702.00 K(-69.2%) | $205.00 K(+122.8%) | $702.00 K(-12.0%) |
| Sept 2014 | - | $92.00 K(-46.9%) | $798.00 K(-59.0%) |
| June 2014 | - | $173.10 K(-25.4%) | $1.95 M(-3.3%) |
| Mar 2014 | - | $231.90 K(-23.0%) | $2.01 M(-11.6%) |
| Dec 2013 | $2.28 M | $301.00 K(-75.7%) | $2.28 M(+4.8%) |
| Sept 2013 | - | $1.24 M(+419.2%) | $2.17 M(+121.1%) |
| June 2013 | - | $239.00 K(-51.8%) | $982.40 K(+25.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2013 | - | $496.10 K(+153.5%) | $780.30 K(+94.7%) |
| Dec 2012 | $400.80 K(-58.3%) | $195.70 K(+279.3%) | $400.80 K(+4.1%) |
| Sept 2012 | - | $51.60 K(+39.8%) | $384.90 K(-33.2%) |
| June 2012 | - | $36.90 K(-68.4%) | $575.90 K(-26.3%) |
| Mar 2012 | - | $116.60 K(-35.2%) | $781.20 K(-18.8%) |
| Dec 2011 | $961.80 K(+120.7%) | $179.80 K(-25.9%) | $961.90 K(+15.0%) |
| Sept 2011 | - | $242.60 K(+0.2%) | $836.40 K(+35.9%) |
| June 2011 | - | $242.20 K(-18.5%) | $615.50 K(+27.4%) |
| Mar 2011 | - | $297.30 K(+447.5%) | $483.30 K(+10.9%) |
| Dec 2010 | $435.80 K(+610.9%) | $54.30 K(+150.2%) | $435.80 K(+6.8%) |
| Sept 2010 | - | $21.70 K(-80.3%) | $408.10 K(-0.9%) |
| June 2010 | - | $110.00 K(-56.0%) | $412.00 K(+33.9%) |
| Mar 2010 | - | $249.80 K(+839.1%) | $307.80 K(+402.1%) |
| Dec 2009 | $61.30 K(-92.9%) | $26.60 K(+3.9%) | $61.30 K(-93.1%) |
| Sept 2009 | - | $25.60 K(+341.4%) | $893.20 K(+44.6%) |
| June 2009 | - | $5800.00(+75.8%) | $617.60 K(-28.3%) |
| Mar 2009 | - | $3300.00(-99.6%) | $861.80 K(+0.2%) |
| Dec 2008 | $859.90 K(>+9900.0%) | $858.50 K(-443.4%) | $859.90 K(>+9900.0%) |
| Sept 2008 | - | -$250.00 K(-200.0%) | $6100.00(-97.6%) |
| June 2008 | - | $250.00 K(>+9900.0%) | $256.10 K(+4098.4%) |
| Mar 2008 | - | $1400.00(-70.2%) | $6100.00(-6.2%) |
| Dec 2007 | $6500.00(-39.3%) | $4700.00(>+9900.0%) | $6500.00(0.0%) |
| Sept 2007 | - | $0.00(0.0%) | $6500.00(-47.6%) |
| June 2007 | - | $0.00(-100.0%) | $12.40 K(0.0%) |
| Mar 2007 | - | $1800.00(-61.7%) | $12.40 K(+17.0%) |
| Dec 2006 | $10.70 K(+181.6%) | $4700.00(-20.3%) | $10.60 K(+79.7%) |
| Sept 2006 | - | $5900.00(>+9900.0%) | $5900.00(+15.7%) |
| Dec 2002 | $3800.00(-25.5%) | - | - |
| Dec 2001 | $5100.00(-84.7%) | $0.00(0.0%) | $5100.00(0.0%) |
| Sept 2001 | - | $0.00(-100.0%) | $5100.00(-47.4%) |
| June 2001 | - | $3600.00(+140.0%) | $9700.00(-64.6%) |
| Mar 2001 | - | $1500.00(>+9900.0%) | $27.40 K(-18.0%) |
| Dec 2000 | $33.40 K(-79.3%) | $0.00(-100.0%) | $33.40 K(-64.9%) |
| Sept 2000 | - | $4600.00(-78.4%) | $95.10 K(+5.1%) |
| June 2000 | - | $21.30 K(+184.0%) | $90.50 K(-46.5%) |
| Mar 2000 | - | $7500.00(-87.8%) | $169.20 K(+4.6%) |
| Dec 1999 | $161.70 K(+61.7%) | $61.70 K(>+9900.0%) | $161.70 K(+61.7%) |
| Sept 1999 | - | $0.00(-100.0%) | $100.00 K(0.0%) |
| June 1999 | - | $100.00 K(>+9900.0%) | $100.00 K(0.0%) |
| June 1998 | - | $0.00(0.0%) | $100.00 K(0.0%) |
| June 1998 | $100.00 K(0.0%) | - | - |
| Mar 1998 | - | $0.00(-100.0%) | $100.00 K(0.0%) |
| Dec 1997 | - | $100.00 K(>+9900.0%) | $100.00 K(0.0%) |
| June 1995 | $100.00 K | $0.00(0.0%) | $100.00 K(0.0%) |
| Mar 1995 | - | $0.00(-100.0%) | $100.00 K(0.0%) |
| Dec 1994 | - | $100.00 K | $100.00 K |
FAQ
- What is Lineage Cell Therapeutics annual capital expenditures?
- What is the all time high annual CAPEX for Lineage Cell Therapeutics?
- What is Lineage Cell Therapeutics annual CAPEX year-on-year change?
- What is Lineage Cell Therapeutics quarterly capital expenditures?
- What is the all time high quarterly CAPEX for Lineage Cell Therapeutics?
- What is Lineage Cell Therapeutics quarterly CAPEX year-on-year change?
- What is Lineage Cell Therapeutics TTM capital expenditures?
- What is the all time high TTM CAPEX for Lineage Cell Therapeutics?
- What is Lineage Cell Therapeutics TTM CAPEX year-on-year change?
What is Lineage Cell Therapeutics annual capital expenditures?
The current annual CAPEX of LCTX is $674.00 K
What is the all time high annual CAPEX for Lineage Cell Therapeutics?
Lineage Cell Therapeutics all-time high annual capital expenditures is $5.33 M
What is Lineage Cell Therapeutics annual CAPEX year-on-year change?
Over the past year, LCTX annual capital expenditures has changed by +$261.00 K (+63.20%)
What is Lineage Cell Therapeutics quarterly capital expenditures?
The current quarterly CAPEX of LCTX is $112.00 K
What is the all time high quarterly CAPEX for Lineage Cell Therapeutics?
Lineage Cell Therapeutics all-time high quarterly capital expenditures is $2.45 M
What is Lineage Cell Therapeutics quarterly CAPEX year-on-year change?
Over the past year, LCTX quarterly capital expenditures has changed by -$27.00 K (-19.42%)
What is Lineage Cell Therapeutics TTM capital expenditures?
The current TTM CAPEX of LCTX is $291.00 K
What is the all time high TTM CAPEX for Lineage Cell Therapeutics?
Lineage Cell Therapeutics all-time high TTM capital expenditures is $5.81 M
What is Lineage Cell Therapeutics TTM CAPEX year-on-year change?
Over the past year, LCTX TTM capital expenditures has changed by -$276.00 K (-48.68%)